Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13273562 | 1.00 | ALOX15 (0.33) | ALOX15ALOX12ALDH1A1MMP2MMP9 | |
| SCHEMBL16021225 | 0.87 | ALOX15 (0.35) | ALOX15ALOX12MMP2MMP9MMP8 | |
| SCHEMBL8931834 | 0.86 | ALDH1A1 (0.33) | ALDH1A1MMP9MMP8 | |
| SCHEMBL15384680 | 0.83 | MMP9 (0.35) | ALOX15ALOX12MMP2MMP9MMP8 | |
| SCHEMBL17920099 | 0.81 | MMP9 (0.37) | ALOX15ALOX12ALDH1A1MMP2MMP9 | |
| SCHEMBL13183932 | 0.81 | MMP8 (0.30) | ALDH1A1MMP9MMP8 | |
| SCHEMBL10281212 | 0.81 | ALOX15 (0.32) | ALOX15ALOX12 | |
| SCHEMBL1709991 | 0.81 | MMP1 (0.32) | MMP9 | |
| SCHEMBL15187001 | 0.80 | ALOX15 (0.36) | ALOX15ALOX12ALDH1A1 | |
| SCHEMBL1709985 | 0.76 | BACE1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090671-B2 | Macrocyclic peptides | SCYNEXIS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| WO-2013028615-A2 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | S&T GOLBAL INC. (US) | 2013-02-28 | — | — | WO | disclosed |
| US-20090312300-A1 | NOVEL MACROCYCLIC PEPTIDES | CYPRALIS LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090306033-A1 | NOVEL CYCLIC PEPTIDES | SCYNEXIS, INC. | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306033-A1 | NOVEL CYCLIC PEPTIDES | VIP, NGLY1, GRPR | ALOX15 4021/4885ALOX12 4151/4885ALDH1A1 3975/4885 |
| US-20090312300-A1 | NOVEL MACROCYCLIC PEPTIDES | CHP1, SARS1, HAVCR2 | ALOX15 4400/4885ALOX12 4613/4885ALDH1A1 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.